RxDoctor Payments Data

Deborah Ahern

Adult Health · East Meadow, NYNPI 1326351560

Payments from drug & device makers

$788in general payments, 2019–2025

Across 24 payments — averaging $32.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$122
  • Scpharmaceuticals Inc.$118
  • Kestra Medical Technology Services, Inc.$92
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$86
  • Pfizer$68
  • Boston Scientific$59
  • plus $242 from 7 others

What the payments were for

  • Food & beverage$788100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$788 in reported general payments places this provider in the 65th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$6,728
Medicare patients
29
Services billed
92

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan82$109,931
FarxigaDapagliflozin Propanediol73$63,989
EliquisApixaban46$51,817
JardianceEmpagliflozin37$36,258
Metoprolol Succinate97$1,700
Atorvastatin Calcium91$982
Captopril11$360
Isosorbide Mononitrate ErIsosorbide Mononitrate28$355
Digoxin16$338
Spironolactone46$271
Furosemide50$245
Hydralazine Hcl19$201
Carvedilol25$170
Lisinopril35$118
Amlodipine Besylate25$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$28$109,93182 claims
AstraZenecaFarxiga$122$63,98973 claims
PfizerEliquis$68$51,81746 claims
Boehringer IngelheimJardiance$32$36,25837 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,828 adult health providers in New York.

Other adult health in East Meadow

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →